Compare UEIC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UEIC | BOLD |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 60.8M |
| IPO Year | 1995 | 2024 |
| Metric | UEIC | BOLD |
|---|---|---|
| Price | $4.31 | $2.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.50 | ★ $4.00 |
| AVG Volume (30 Days) | 97.9K | ★ 233.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.78 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $368,288,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.69 | $0.96 |
| 52 Week High | $5.99 | $3.16 |
| Indicator | UEIC | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 38.77 | 65.15 |
| Support Level | $3.87 | $2.71 |
| Resistance Level | $4.43 | $2.97 |
| Average True Range (ATR) | 0.33 | 0.14 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 4.35 | 41.63 |
Universal Electronics Inc is engaged in universal wireless control solutions for the home. The company design, develop, manufacture, ship and support climate control solutions, wireless sensor and smart home control products, home entertainment control products, technology and software solutions and audio-video (AV) accessories that are used by the world's brands in the climate control, security, home automation, home appliance, home entertainment and consumer electronics markets.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.